´ë·®±¸¸ÅȨ >
ÀÚ¿¬°ú °úÇÐ
>
ÀÇÇÐ/»ý¸íÀÇ ÀÌÇØ
>
ÀÇÇÐÀ̾߱â

¾à±¹¿¡¼­ ½áº» µÎ ¹ø° ¾àÀ̾߱â
Á¤°¡ 25,000¿ø
ÆǸŰ¡ 25,000¿ø (0% , 0¿ø)
I-Æ÷ÀÎÆ® 750P Àû¸³(3%)
ÆǸŻóÅ ÆǸÅÁß
ºÐ·ù ÀÇÇÐÀ̾߱â
ÀúÀÚ ¹ÚÁ¤¿Ï , ¹ÚÁ¤¿Ï
ÃâÆÇ»ç/¹ßÇàÀÏ Âü¾à»ç / 2019.04.30
ÆäÀÌÁö ¼ö 278 page
ISBN 9791196168025
»óÇ°ÄÚµå 307644246
°¡¿ëÀç°í Àç°íºÎÁ·À¸·Î ÃâÆÇ»ç ¹ßÁÖ ¿¹Á¤ÀÔ´Ï´Ù.
 
ÁÖ¹®¼ö·® :
´ë·®±¸¸Å Àü¹® ÀÎÅÍÆÄÅ© ´ë·®ÁÖ¹® ½Ã½ºÅÛÀ» ÀÌ¿ëÇÏ½Ã¸é °ßÀû¿¡¼­ºÎÅÍ ÇàÁ¤¼­·ù±îÁö Æí¸®ÇÏ°Ô ¼­ºñ½º¸¦ ¹ÞÀ¸½Ç ¼ö ÀÖ½À´Ï´Ù.
µµ¼­¸¦ °ßÀûÇÔ¿¡ ´ãÀ¸½Ã°í ½Ç½Ã°£ °ßÀûÀ» ¹ÞÀ¸½Ã¸é ±â´Ù¸®½Ç ÇÊ¿ä¾øÀÌ ÇÒÀιÞÀ¸½Ç ¼ö ÀÖ´Â °¡°ÝÀ» È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
¸ÅÁÖ ¹ß¼ÛÇØ µå¸®´Â ÀÎÅÍÆÄÅ©ÀÇ ½Å°£¾È³» Á¤º¸¸¦ ¹Þ¾Æº¸½Ã¸é »óÇ°ÀÇ ¼±Á¤À» ´õ¿í Æí¸®ÇÏ°Ô ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.

 ´ë·®±¸¸ÅȨ  > ÀÚ¿¬°ú °úÇÐ  > ÀÇÇÐ/»ý¸íÀÇ ÀÌÇØ  > ÀÇÇÐÀ̾߱â

¾à±¹¿¡¼­ ½á º» ¾à À̾߱⠼¼Æ® 120,000¿ø (0%)
¾à±¹¿¡¼­ ½áº» ¼¼ ¹ø° ¾àÀ̾߱â 25,000¿ø (0%)
¾à±¹¿¡¼­ ½áº» µÎ ¹ø° ¾àÀ̾߱â 25,000¿ø (0%)
¾à±¹¿¡¼­ ½áº» ù ¹ø° ¾àÀ̾߱â 25,000¿ø (0%)
        
 

 
¸ñÂ÷
[¸ñÂ÷] ÃßõÀÇ ±Û Ã¥ ¸Ó¸®¿¡ 64 Cytochrome P450 65 Cytochrome P450ÀÇ »õ·Î¿î target 66 cytochrom p450 °ü·Ã¾à¹° 67 º´¿ë±Ý±â Á¤¸® 68 Orphan Drug 69 Prodrug 70 À¯È¿±â°£ °æ°ú ÀǾàÇ° 71 ±¸°­ºØÇØÁ¤(orally disintegrating tablets) 72 Sodium channelÀ» Â÷´ÜÇÏ´Â ¾à¹° 73 ºÎÁ¤¸Æ Ä¡·á¾à¹° 74 Amiodarone(ÄÚ´Ù·Ð) 75 QT ¿¬Àå¾à¹° 76 Acyclovir 77 Influenza 78 Ç׿øº¸°­Á¦ Adjuvant 79 Gardasil°ú Cervarix À̾߱â 80 RotaTeq°ú Rotarix 81 Clopidogrel(Çöóºò½º) 82 PPAR agonist 83 Insulin ¿¡¼­ ÀÌÁ¦´Â Incretin ½Ã´ë 84 ù ¹ø° GLP-1 ¾à¹°ÀÎ exenatide(¹ÙÀÌ¿¡Å¸) 85 DPP-4 ¾ïÁ¦Á¦ 86 SGLT-2 ¾ïÁ¦Á¦ 87 È£Áß±¸ °¨¼ÒÁõ 88 Calcineurin inhibitor 89 ¸é¿ª ¾ïÁ¦Á¦ mTOR 90 Cytokine°ú ·ù¸¶Æ¼½º °üÀý¿° 91 HIVÄ¡·áÁ¦ Zidovudine¿¡¼­ Fuzeon±îÁö 92 Ç×ü ÀǾàÇ° 93 ÀӽŠÁø´Ü ½Ã¾à 94 ÃÖÃÊÀÇ Ç¥Àû Ç×¾ÏÁ¦ ±Û¸®º¤(Imatinib) 95 Epidermal growth factor receptor(EGFR) -TKI ÀúÇØÁ¦ 96 HER2 ÀúÇØÁ¦ 97 Bevacizumab(¾Æ¹Ù½ºÆ¾) 98 Multi Targeted Anticancer Agents 99 Tofacitinib(Á©ÀÜÁî)°ú Ruxolitinib (ÀÚÄ«ºñ) 100 Crizotinib(ÀêÄÚ¸®) 101 Muscle relaxant°ú acetylcholine 102 Àü¸³¼± ºñ´ëÁõ ¾à¹° 103 Hazardous drug 104 5-HT ¼ö¿ëü 105 Ç×¾Ï Ä¡·á½Ã ±¸Åä ¾ïÁ¦Á¦ aprepitant(¿¡¸àµå) 106 ÈíÀÔ±â 107 Chronotherapy 108 Desmopressin(¹Ì´Ï¸°) 109 °á¼®°ú Potassium Citrate(À¯·Î½ÃÆ®¶ó) 110 carbonic anhydrase inhibitor 111 ħ°ú pilocarpine 112 Prostaglandin°è ³ì³»Àå ¾à¹° 113 öÁßµ¶°ú Deferasirox(¿¢½ºÀÚÀ̵å) 114 °è¸é È°¼ºÁ¦ Àǹ̸¦ °¡Áö´Â ¾à¹° 115 Phosphate binders(ÀÎ °áÇÕÁ¦) 116 ºñ¸¸ °ü·Ã ¾à¹° 117 ¸¸¼º ½ÅºÎÀü ¾à¹° 118 Bisphosphonate 119 Åëdz °ü·Ã¾à¹° 120 Àλ絹°ú À̸ðÆ° 121 Ubidecarenone 122 Àç¹Ì·Î ÀÐ¾î º¸´Â ¾î¿ø À̾߱â INDEX

ÀúÀÚ
¹ÚÁ¤¿Ï
ÀλýÀÇ ´ëºÎºÐÀ» ¾à»ç·Î È°µ¿ÇÏ´Ù°¡ µÚ´Ê°Ô ±×¸²Ã¥ ¼¼°è¿¡ ¹ßÀ» µé¿©³õ¾Ò´Ù. ±×¸²°ú À̾߱Ⱑ ÁÁ¾Æ¼­, ¾ÆÀ̵é°ú ÇÔ²² ³ª´­ ¼ö ÀÖ´Â °Ô ÁÁ¾Æ¼­ ±×¸²Ã¥ ÀÛ°¡°¡ µÇ¾ú´Ù. ù Ã¥ [¾Æ±â Áã°¡ ÀáÀÚ·¯ °¡¿ä]·Î 2011³â º¼·Î³Ä ±¹Á¦ ¾î¸°ÀÌ µµ¼­Àü¿¡¼­ ¡®¿ÃÇØÀÇ ÀÏ·¯½ºÆ®·¹ÀÌÅÍ¡¯·Î ¼±Á¤µÇ¾ú´Ù. À̹ø [½£ ¼Ó ¾à±¹ ³îÀÌ]´Â µþ°ú 6°³¿ù µÈ ¿Ü¼Õ³à¸¦ »ý°¢Çϸç ÀÛ¾÷Çß´Ù. ÀÛÇ°À¸·Î ±×¸²Ã¥ [¾ö¸¶ ¾îµð ÀÖ¾î¿ä?]¿Í [À¯¸® ¾¾¾Ñ]ÀÌ ÀÖ´Ù.
   ¾Æ±â Áã°¡ ÀáÀÚ·¯ °¡¿ä | ¹ÚÁ¤¿Ï | ½Ã°øÁִϾî
   ½£ ¼Ó ¾à±¹ ³îÀÌ | ¹ÚÁ¤¿Ï | ½Ã°øÁִϾî
   ¾à±¹¿¡¼­ ¾Ë·ÁÁØ ±Ã±ÝÇÑ ¾à À̾߱â | ¹ÚÁ¤¿Ï | Á¶À±Ä¿¹Â´ÏÄÉÀ̼Ç
   ¾à±¹¿¡¼­ ½áº» ù ¹ø° ¾àÀ̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç
   ¾à±¹¿¡¼­ ½áº» ¼¼ ¹ø° ¾àÀ̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç
¹ÚÁ¤¿Ï
´ëÇб³¿¡¼­ ¾àÇÐÀ» °øºÎÇÏ°í ¾à»ç°¡ µÇ¾ú´Ù. ±×·¯³ª ±×¸²À» ±×¸®°í ½ÍÀº ²ÞÀ» ¹ö¸± ¼ö ¾ø¾î ´ëÇпø¿¡ ÁøÇÐÇØ ±×¸² °øºÎ¸¦ ½ÃÀÛÇß°í, ±×¸²Ã¥À» ¸¸µé°í ½Í¾î¼­ ±×¸²Ã¥ ¿öÅ©¼ó¿¡ Âü¿©Çß´Ù. '¾Æ±â Áã°¡ ÀáÀÚ·¯ °¡¿ä'´Â ¼¼»ó¿¡ ¼±º¸À̴ ù ±×¸²Ã¥À̸ç, ÀÌ ±×¸²Ã¥À» ¸¸µé¸é¼­ ¿¬½ÀÇÏ°í ÁغñÇß´ø ±×¸²À» 2011³â º¼·Î³Ä ±¹Á¦ ¾î¸°ÀÌ µµ¼­°üÀü¿¡ ÃâÇ°ÇÏ¿© '¿ÃÇØÀÇ ÀÏ·¯½ºÆ®·¹ÀÌÅÍ'¿¡ ¼±Á¤µÇ¾ú´Ù. µ¿ÆÇÈ­¿Í ÄݶóÁÖ¸¦ È¥ÇÕÇØ Àá ¸ø ÀÌ·ç´Â ¿©ÀÚ¾ÆÀÌÀÇ ¿¹¹ÎÇÏ°í ¼¶¼¼ÇÑ ¸¶À½, Àû¸·ÇÏ°í ÀÜÀÜÇÑ ÇѹãÀÇ Á¤°æÀ» ¾Æ¸§´ä°Ô Ç¥ÇöÇØ ³Â´Ù. ¾Æ¸§´ä°í °¨µ¿À» ÁÖ´Â ±×¸²Ã¥À» ¸¸µé±â À§ÇØ Áö±Ýµµ À̾߱Ⱑ ÀÖ´Â ±×¸²À» ±×¸®°í ÀÖ´Ù.
   ¾Æ±â Áã°¡ ÀáÀÚ·¯ °¡¿ä | ¹ÚÁ¤¿Ï | ½Ã°øÁִϾî
   ½£ ¼Ó ¾à±¹ ³îÀÌ | ¹ÚÁ¤¿Ï | ½Ã°øÁִϾî
   ¾à±¹¿¡¼­ ¾Ë·ÁÁØ ±Ã±ÝÇÑ ¾à À̾߱â | ¹ÚÁ¤¿Ï | Á¶À±Ä¿¹Â´ÏÄÉÀ̼Ç
   ¾à±¹¿¡¼­ ½áº» ù ¹ø° ¾àÀ̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç
   ¾à±¹¿¡¼­ ½áº» ¼¼ ¹ø° ¾àÀ̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç

ÀÌ ÃâÆÇ»çÀÇ °ü·Ã»óÇ°
¾à±¹¿¡¼­ ½á º» ¾à À̾߱⠼¼Æ® | Âü¾à»ç
¾à»çµéÀÌ ´äÇÏ´Â ½ºÆ÷Ã÷ ¿µ¾ç QA | Á¤»ó¿ø | Âü¾à»ç
¾à±¹¿¡¼­ ½áº» ´Ù¼¸ ¹ø° ¾à À̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç
ÇÑ ±ÇÀ¸·Î ³¡³»´Â ¾àÇнûç(2022) | ¼ÕÁøÈÆ,°ûÇý¹Î,ÀÌ»ó°ï,±è¹ÎÁö,±èÁöÀº ¿Ü | Âü¾à»ç
¾à±¹¿¡¼­ ½áº» ³× ¹ø° ¾àÀ̾߱â | ¹ÚÁ¤¿Ï | Âü¾à»ç

ÀÌ ºÐ¾ß ½Å°£ °ü·Ã»óÇ°
¿£µµÅå | ÃÖ¼º¹é,À±¹ÎÈ£ | ¾Ç¾î¹Ìµð¾î
´ãµµÇÐ | ´ëÇÑÃéÀå´ãµµÇÐȸ | ±ºÀÚÃâÆÇ»ç
2025´ëºñ Áøµµº° º¯½Ã¤ý»ç½Ã±âÃ⠹ιý»ç·Ê¿¬½À | ÀÌż· | Çп¬
ÀÇ·á±â±â ÀÎÇã°¡(2024) | ±èÁ¾Çö,±è¸í±³ | À§Áî´ýÇÃ
(set)ÃÖ½ÅÁö¿ª»çȸº¸°Ç°£È£ÇÐ1,2(ÃÖÀº¼÷¿Ü) | ¼ö¹®»ç
 
µµ¼­¸¦ ±¸ÀÔÇϽŠ°í°´ ¿©·¯ºÐµéÀÇ ¼­ÆòÀÔ´Ï´Ù.
ÀÚÀ¯·Î¿î ÀÇ°ß ±³È¯ÀÌ °¡´ÉÇÕ´Ï´Ù¸¸, ¼­ÆòÀÇ ¼º°Ý¿¡ ¸ÂÁö ¾Ê´Â ±ÛÀº »èÁ¦µÉ ¼ö ÀÖ½À´Ï´Ù.

µî·ÏµÈ ¼­ÆòÁß ºÐ¾ß¿Í »ó°ü¾øÀÌ ¸ÅÁÖ ¸ñ¿äÀÏ 5ÆíÀÇ ¿ì¼öÀÛÀ» ¼±Á¤ÇÏ¿©, S-Money 3¸¸¿øÀ» Àû¸³Çص帳´Ï´Ù.
ÃÑ 0°³ÀÇ ¼­ÆòÀÌ ÀÖ½À´Ï´Ù.